This data offers a rationale for combining HDAC inhibitors with inhibitors of the PD-1/PD-L1 axis, including for patients who are refractory or expected not to respond to these therapies alone due to absent or low PD-L1 tumor expression. Here, CD274 is linked to neoplasm.